Program
Saturday, September 27 | Sunday, September 28 |
Monday, September 29
(Program as of August 2014)
Friday, September 26
| 11:00 am | Registration is Open (Viger Foyer) |
| 1:30–6:00 pm | Poster Set up (Viger Hall) |
| 1:30 pm | Ballroom is Open
(All sessions to be held in Ballroom) |
| 3:00-3:10 pm | Introductory Remarks |
| 3:10-4:00 pm | Keynote Address Kenneth Fearon, MD, MBBch. Hons. Professor of Surgical Oncology University of Edinburgh United Kingdom |
| Session 1 Diagnostics and Biomarkers in Cancer Cachexia |
|
|---|---|
| (Chair: Daniel Marks, MD, PhD) | |
| 4:15-4:45 pm | Body Composition and Prognostication in Cancer Vickie Baracos, PhD Professor and Alberta Cancer Foundation Chair in Palliative Medicine Department of Oncology University of Alberta Edmonton Alberta, Canada |
| 4:45-5:15 pm | Myostatin as a Marker of Cachexia in Gastric Cancer
Maurizio Muscaritoli, PhD Professor Department of Clinical Medicine Sapienza, University of Rome Rome, Italy |
| 5:15-5:45 pm | Cutting Edge Science in Cancer Cachexia
(5 min teaser presentations from posters) |
| Role of Activin A in Human Cancer Cachexia (ACTICA study) Jean Paul Thissen, PhD (Brussels, Belgium) |
|
| Human Cancer Cachexia Pathways: Implications of Muscle Ageing? Carson Jacobi, PhD (Novartis, Basel, Switzerland) |
|
| Prehabilitation vs Rehabilitation: A Randomized Control Trial in Patients Undergoing Colorectal Resection for Cancer
Rashami Awasthi (Concordia University, Montreal, Canada) |
|
| NEO1940: A Novel Cannabinoid Receptor Agonist with Reduced Brain Exposure as a Multimodal Supportive Care Therapy in Cancer Patients with Anorexia and Weight Loss
Sultan Ahmad, PhD (NEOMED Institute, Montréal, Canada) |
|
| Cachexia Evolution in Renal Cell Carcinoma Patients and its Relation with Cardiac Ejection Fraction Evaluated by MUGA Scan
Seyyed Mohammad Reza Kazemi-Bajestani (University of Alberta, Alberta, Canada) |
|
| 6:00-8:00 pm | Welcoming Reception
(Salon Maisonneuve ABC – 36th floor) |
| 8:00–10:00 pm | Poster Viewing (Viger Hall) Coffee & dessert (Viger Foyer) |
Saturday, September 27
| 6:30-8:00 am | Breakfast (Salon Maisonneuve ABC – 36th floor) |
| Session 2 Mechanisms of Muscle Wasting in Cancer Cachexia: Part I |
|
|---|---|
| (Chair: Teresa Zimmers, PhD) | |
| 8:00-8:30 am | The Role of p38beta MAPK in Cachexia
Yi-Ping Li, PhD Associate Professor Department of Integrative Biology and Pharmacology University of Texas Health Science Center Houston, Texas, USA |
| 8:30-9:00 am | Uncovering IL-6-independent mechanisms involved in STAT3-induced Cachexia Imed Gallouzi, PhD Professor Biochemistry Department & Goodman Cancer Center McGill University Montreal, Quebec, Canada |
| 9:00-9:15 am | BMP Axis in Experimental Cancer Cachexia Roberta Sartori, PhD Venetian Institute of Molecular Medicine Padova, Italy |
| 9:15-9:30 am | Exploring New Targets within the TGFβ Signaling Network as Interventions
for Cachexia
Paul Gregorevic, PhD Laboratory Head Baker IDI Heart and Diabetes Institute Melbourne, Australia |
| 9:30-9:45 am | Myofilament protein content and muscle function in cancer patients Michael Toth, PhD Department of Medicine University of Vermont College of Medicine Burlington, Vermont, USA |
| 9:45-10:15 am | Coffee Break
(Viger Foyer) |
| 10:15-10:45 am | Myostatin Function in Cancer Cachexia Mridula Sharma, PhD Associate Professor Department of Biochemistry, National University of Singapore Singapore |
| 10:45-11:15 am | Cytokine Regulation of Muscle Wasting in Cachexia Josep Argilés, PhD Professor University of Barcelona, Department of Biochemistry and Molecular Biology Barcelona, Spain |
| 11:15-11:30 am | Role of the USP19 deubiquitylating enzyme in muscle wasting and myogenesis Simon S. Wing, MD Professor McGill University Montreal, Quebec, Canada |
| 11:30-12:00 pm | Cutting Edge Science in Cancer Cachexia
(5 min teaser presentations from posters) |
| Persistent C/EBPβ Expression in Muscle Satellite Cells Contributes to the Pathogenesis of Cancer Cachexia
Nadine Wiper-Bergeron, PhD (University of Ottawa, Ottawa, Canada) |
|
| Inhibition of FoxO Prevents Cancer-Induced Diaphragm Atrophy and Inhibits
Cardiac Pathology
Andrew Judge, PhD (University of Florida, Gainesville, USA) |
|
| What is the impact of AMPK activation on cytokine-induced muscle atrophy?
Derek Hall (McGill University, Montreal, Canada) |
|
| Inhibition of JAK/STAT3 Pathway with Ruxolitinib and Tofacitinib Does Not
Block Skeletal Muscle Atrophy in C-26 Cancer Cachexia Model
Tianshun Xu, PhD (GlaxoSmithKline, Durham, USA) |
|
| 12:00-1:30 pm | Lunch (Salon Maisonneuve ABC – 36th floor) |
| Session 3 Cachexia Promoters from Outside the Myofiber |
|
| (Chair: Maurizio Muscaritoli, PhD) | |
| 1:30-2:00 pm | Neuroendocrine influences in Cachexia Daniel Marks, MD, PhD Professor, Pediatric Endocrinology Credit Union for Kids Professor in Pediatric Research Oregon Health & Science University Portland, Oregon, USA |
| 2:00-2:30 pm | The Role of the Muscle Stem Cell Niche in Regulating Regenerative Myogenesis Michael Rudnicki, OC, PhD, FRSC Professor, Department of Medicine, University of Ottawa Senior Scientist & Director Regenerative Medicine Program Ottawa Hospital Research Institute Ottawa, Ontario, Canada |
| 2:30-2:45 pm | Tumor-derived GM-CSF Enhances Cancer-Associated Cachexia by Promoting Increased Adipocyte Lipolysis Aaron Laine, MD, PhD Resident Radiation Oncology UT Southwestern Medical Center Dallas, Texas, USA |
| 2:45-3:00 pm | Cancer-Associated Cachexia: A switch from White to Brown Fat due to systemic inflammation leads to organ wasting Erwin Wagner, PhD Professor BBVA Foundation-CNIO Cancer Cell Biology Program Madrid, Spain |
| 3:00-3:15 pm | Muscle Wasting and Impaired Myogenesis in Cachexia Paola Costelli, PhD Professor, Department of Clinical and Biological Science University of Torino Torino, Italy |
| 3:15-3:45 pm | Coffee Break (Viger Foyer) |
| 3:45-4:15 pm | SOCS3 is a bi-functional buffer of muscle growth and wasting Teresa Zimmers, PhD Associate Professor, Department of Surgery IU Simon Cancer Center Indiana University, School of Medicine Indianapolis, Indiana, USA |
| 4:15-4:45 pm | Cachexia and the Role of the Muscle Microenvironment Denis Guttridge, PhD Professor, Department of Molecular Virology, Immunology and Medical Genetics The Ohio State University Columbus, Ohio, USA |
| 4:45-5:00 pm | Cancer derived MIC-1/GDF15 induced starvation leads to Cachexia Samuel Breit, PhD Professor St Vincent's Hospital Sydney, Australia |
| 5:00-7:00 pm | Poster Viewing (Judging) (Viger Hall) |
| 7:45 pm | Gala Dinner – Café Caf Conc' Theatre A Tribute to Neil MacDonald, MD and Special Presentation "Palliative Rehabilitation Program Improves Patient Functioning" Research Consultant Bruyere Research Institute Ottawa, Ontario, Canada |
Sunday, September 28
| 6:30-8:00 am | Breakfast (Salon Maisonneuve ABC – 36th floor) |
| Session 4 Mechanisms of Muscle Wasting in Cancer Cachexia: Part II |
|
|---|---|
| (Chair: Josep Argilés, PhD) | |
| 8:00-8:30 am | Ghrelin action in Cachexia Andrea Graziani, PhD Professor Department of Translational Medicine University of Piemonte Orientale Novara, Italy |
| 8:30-9:00 am | Signaling Pathways that Regulate Skeletal Muscle Atrophy and Hypertrophy David Glass, MD Novartis Institutes for Biomedical Research Cambridge, Massachusetts, USA |
| 9:00-9:30 am | Stress, inflammation and cachexia: role of physical activity Dario Coletti, PhD Assistant Professor University Pierre et Marie Curie Paris 06 Paris, France |
| 9:30-10:00 am | Thermogenesis and Altered lipid Metabolism in Cancer Cachexia Graham Robertson, PhD Senior Scientist Tumorkine Group, The Kinghorn Cancer Centre Garvan Institute of Medical Research Sydney, Australia |
| 10:00-10:30 am | Announce Poster Winners; Coffee Break (Viger Foyer) |
| 10:30-10:45 am | TGF-β Mediates Muscle Weakness in Bone Metastases via Oxidation-Induced Calcium Leak David L. Waning, PhD Assistant Research Professor Indiana University Indianapolis, Indiana, USA |
| 10:45-11:00 am | T Cell Function in Diabetes and Cancer-Associated Cachexia Joanna Davies, PhD President and CEO San Diego Biomedical Research Institute San Diego, California, USA |
| 11:00-11:30 am | IL-6 and Mitochondrial Dysfunction in Cachexia James Carson, PhD Professor Department of Exercise Science University of South Carolina Columbia, South Carolina, USA |
| 11:30-12:00 pm | Molecular Signatures of Cancer Cachexia Michel Tremblay, PhD Professor Department of Biochemistry / Goodman Cancer Center McGill University Montreal, Quebec, Canada |
| 12:00-1:30 pm | Lunch & Poster Pick up (Salon Maisonneuve ABC – 36th floor) |
| Session 5 Pre-Clinical to Clinical Studies |
|
| (Chair: Vickie Baracos, PhD) | |
| 1:30-2:00 pm | Metabolic Rearrangement in Cancer Cachexia Marion Couch, MD, PhD Professor, Chair OHNS Department Indiana University School of Medicine Indianapolis, Indiana, USA |
| 2:00-2:30 pm | Malignant Inflammation and its Role in Disease Progression and HPA Mediated Cancer Symptoms Michael Stecher MD Medical Director XBiotech USA Austin, Texas, USA |
| 2:30-3:00 pm | Emerging Approaches to Treating Muscle Atrophy and Weakness Mohamed El Mouelhi, MD, PhD, FACP Executive Director Translational Medicine, Musculoskeletal Novartis Institutes for Biomedical Research East Hanover, NJ, USA |
| 3:00-3:15 pm | HDAC Inhibition as a Therapeutic Strategy for Cancer Cachexia Ching-Shih Chen, PhD Professor of Medicinal Chemistry College of Pharmacy and Comprehensive Cancer Center Ohio State University Columbus, Ohio, USA Institute of Biological Chemistry, Academia Sinica Taipei, Taiwan |
| 3:15-3:45 pm | Coffee Break (Viger Foyer) |
| 3:45-4:15 pm | Targeting GDF15 with the inhibitory antibody AV-380 for the treatment of Cancer Cachexia Lorena Lerner, PhD Director AVEO Oncology Inc. Cambridge, Massachusetts, USA |
| 4:15-4:30 pm | Next Generation Sequencing of the Muscle and Fat Transcriptome in Patients with Cancer Cachexia Reveals Novel Mechanisms Amal H.I. Al Haddad, RN, BSN, MSHRM PhD candidate - Cancer Biology Tract, Prof. Thomas E. Adrian Lab Department of Physiology, College of Medicine United Arab Emirates University Al Ain, United Arab Emirates |
| 4:30-4:45 pm | Baseline Characteristics of Anamorelin Phase III Clinical Trial program (ROMANA), a novel Treatment for Anorexia-Cachexia in Non-Small Cell Lung Cancer (NSCLC) Patients Speaker for Helsinn |
| 4:45-5:15 pm | Ghrelin Therapy in Cancer Cachexia Jose M. Garcia, MD, PhD Assistant Professor Departments of Medicine and Molecular and Cell Biology Baylor College of Medicine Houston, Texas, USA |
| 5:15pm | Closing Remarks |